Avivagen Inc. (VIV.V)
| Previous Close | 0.0500 |
| Open | 0.0550 |
| Bid | 0.0500 x 0 |
| Ask | 0.0550 x 0 |
| Day's Range | 0.0500 - 0.0550 |
| 52 Week Range | 0.0500 - 0.2400 |
| Volume | |
| Avg. Volume | 51,739 |
| Market Cap | 3.708M |
| Beta (5Y Monthly) | 0.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings Date | Jun 13, 2023 - Jun 19, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.38 |
- Simply Wall St.
Avivagen First Quarter 2023 Earnings: CA$0.015 loss per share (vs CA$0.027 loss in 1Q 2022)
Avivagen ( CVE:VIV ) First Quarter 2023 Results Key Financial Results Revenue: CA$66.0k (down 76% from 1Q 2022). Net...
- Business Wire
Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2023
OTTAWA, Ontario, March 17, 2023--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of 2023.
- Business Wire
Avivagen Reports Fiscal Year 2022 Financial Results and Strategic Initiatives to Accelerate Growth
OTTAWA, Ontario, February 21, 2023--Avivagen Inc. (TSXV:VIV) ("Avivagen", the "Corporation"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, today reported its audited financial results for the year ended October 31, 2022 and the implementation of a strategic plan to accelerate growth.
